Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma

BACKGROUND: Dimethyl fumarate (DMF), an oral agent approved for the treatment of relapsing–remitting multiple sclerosis (RRMS), has promising preclinical activity against glioblastoma (GBM). This phase I study sought to determine the recommended phase 2 dose (RP2D) of DMF and evaluate its safety and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Shafer, Danielle, Tombes, Mary Beth, Shrader, Ellen, Ryan, Alison, Bandyopadhyay, Dipankar, Dent, Paul, Malkin, Mark
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212848/
https://ncbi.nlm.nih.gov/pubmed/32642720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz052
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados